Zobrazeno 1 - 10
of 811
pro vyhledávání: ''
Autor:
Nancy Chan, Jiuping Ji, Antoinette R. Tan, Janice M. Mehnert, Alice P. Chen, Jan H. Beumer, Mansi Shah, Joseph Aisner, Murugesan Gounder, Jyoti Malhotra, Rebecca A. Moss, Yong Lin, Brian F. Kiesel, Hongxia Lin, Mark N. Stein, Michael P. Kane
Publikováno v:
Cancer Chemother Pharmacol
Purpose Veliparib (V), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, potentiates effects of alkylating agents and topoisomerase inhibitors in preclinical tumor models. We conducted a phase I trial of V with iv cyclophosphamide (C) and V plus
Autor:
Raphael Teipel, Susanne Quick, Stephan Richter, Holger Knoth, Theresa Kretschmann, Frank Kroschinsky, Christoph Röllig, Ekaterina Balaian, Nael Alakel, Martin Bornhäuser, Sandra Heuschkel, Malte von Bonin, Simone von Bonin
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose High-dose methotrexate (HDMTX)-associated acute kidney injury with delayed MTX clearance has been linked to an excess in MTX-induced toxicities. Glucarpidase is a recombinant enzyme that rapidly hydrolyzes MTX into non-toxic metabolites. The
Autor:
Cristina Matteo, Giovanni Schininà, Nunziatina Laura Parrinello, Roberta Sciortino, Salvatore Leotta, Giuseppe Milone, Gianna Maria Piccolo, Massimo Zucchetti, Francesco Di Raimondo, Maria Grazia Camuglia, Annalisa Condorelli, Maria Proietto
Publikováno v:
Cancer Chemotherapy and Pharmacology. 89:267-270
Relapse at the central nervous system (CNS) in acute myeloid leukemia (AML) carries a dismal prognosis. Treatment options are limited to intrathecal therapy, high-dose cytarabine, high-dose methotrexate, and radiotherapy. Novel strategies are needed.
Autor:
Donald P. Bottaro, Ralph E. Parchment, Larry Rubinstein, Barry C. Johnson, Woondong Jeong, Young H. Lee, Khanh T. Do, Apurva K. Srivastava, James H. Doroshow, John Wright, Alice P. Chen, S. Kummar, Tony Navas, Andrea Regier Voth, Fabiola Cecchi, Sook Ryun Park
Publikováno v:
Investigational New Drugs
The vascular endothelial growth factor (VEGF)/VEGFR and hepatocyte growth factor (HGF)/c-MET signaling pathways act synergistically to promote angiogenesis. Studies indicate VEGF inhibition leads to increased levels of phosphorylated c-MET, bypassing
Autor:
Dermot F. McGinnity, Diansong Zhou, Shringi Sharma, Buyun Chen, Venkatesh Pilla Reddy, Karthick Vishwanathan, Adrian J. Fretland, Joseph Ware, Yan Xu
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Limited information is available regarding the drug–drug interaction (DDI) potential of molecular targeted agents and rituximab plus cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine (Oncovin), and prednisone (R-CHOP) therapy
Autor:
Zeev Estrov, Prithviraj Bose, Varsha Gandhi, Jan A. Burger, Xuemei Wang, Naveen Garg, Rashmi Kanagal-Shamanna, Naveen Pemmaraju, Philip A. Thompson, Ana Ayala, Hagop M. Kantarjian, Koji Sasaki, Keyur P. Patel, Tapan M. Kadia, Alessandra Ferrajoli, Susan O'Brien, Elias Jabbour, Gautam Borthakur, Koichi Takahashi, Marina Konopleva, Wanda Lopez, Michael J. Keating, Wei Wang, William G. Wierda, Nitin Jain, Jeffrey L. Jorgensen, William Plunkett, Sa Wang
Publikováno v:
Leukemia. 35:3421-3429
Chemoimmunotherapy with combined fludarabine, cyclophosphamide and rituximab (FCR) has been an effective treatment for patients with chronic lymphocytic leukemia (CLL). We initiated a phase II trial for previously untreated patients with CLL with mut
Autor:
Sapna Pradyuman Patel, David S. Hong, Vivek Subbiah, Amanda Johnston, Siqing Fu, John S. Bomalaski, Sarina Anne Piha-Paul, Shuyang Yao, Ahmed Kaseb, Aung Naing, Nai Shi, Filip Janku, Apostolia Maria Tsimberidou, Shannon N. Westin, John Stewart
Publikováno v:
Br J Cancer
Background Arginine depletion interferes with pyrimidine metabolism and DNA damage-repair pathways, and pairing arginine deiminase pegylated with 20,000-molecular-weight polyethylene glycol (ADI-PEG20) with platinum enhances cytotoxicity in vitro and
Autor:
Ben L. Sanford, Martin S. Tallman, Richard F. Schlenk, Lucas J. Huebner, Jürgen Krauter, Hartmut Döhner, Maria Teresa Voso, Hubert Serve, Andrew H. Wei, Jorge Sierra, Bruno C. Medeiros, Dietger Niederwieser, Arnold Ganser, Insa Gathmann, Miguel A. Sanz, Joseph Brandwein, Rebecca B. Klisovic, Sergio Amadori, Christian Thiede, Thomas W. Prior, Richard A. Larson, Theo de Witte, Konstanze Döhner, Kristina Laumann, Richard Stone, Clara D. Bloomfield, Frederick R. Appelbaum, Guido Marcucci, Gerhard Ehninger, Ilene Galinsky, Susan Geyer, Sumithra J. Mandrekar
Publikováno v:
Leukemia, 35, 9, pp. 2539-2551
Leukemia, 35, 2539-2551
Leukemia
LEUKEMIA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
Leukemia, 35, 2539-2551
Leukemia
LEUKEMIA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
Contains fulltext : 237748.pdf (Publisher’s version ) (Closed access) The prospective randomized, placebo-controlled CALGB 10603/RATIFY trial (Alliance) demonstrated a statistically significant overall survival benefit from the addition of midostau
Publikováno v:
Journal of Neuro-Oncology. 151:331-338
The study the characteristics of surgical meningiomas in female patients who took CPA and to compare this population to a non-CPA control group. We processed the French Systeme National des Donnees de Sante (SNDS) database to retrieve appropriate cas
Autor:
Carlos Gomez-Roca, Sylvie Rottey, Thierry Lesimple, Céleste Lebbé, Ahmad Awada, Celine Pages, Antoine Italiano, Philippe Aftimos, Richard F. Kefford, Armin Schueler, Jean Pierre Delord, Vibeke Kruse, Samantha Goodstal, Nadine Houede, Monica Dinulescu, Suzanne Leijen, Jan H.M. Schellens, Sandrine Faivre, Giorgio Massimini, Eric Raymond
Publikováno v:
Targeted Oncology. 16:47-57
Pimasertib is a selective, potent mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor. The aim of this study was to describe the efficacy, safety, and pharmacodynamics of pimasertib at pharmacologically active doses in a cohort of patients wi